Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
29.4.2025 09:00:00 CEST | news aktuell GmbH | Press release
Tübingen, Germany, April 29, 2025
Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Cisplatin is a cornerstone in modern oncology and is used annually in more than 500,000 cancer patients worldwide. Its introduction in the late 1970s revolutionized testicular cancer treatment, improving the 5-year survival rate (from just 5% to 98%). However, its life-saving efficacy is often overshadowed by severe side effects, with permanent, bilateral hearing loss among the most debilitating. Studies indicate that up to 80% of patients treated with cisplatin may experience clinically-relevant hearing loss.
The PROHEAR Study is a placebo-controlled, randomized, double-blind, split-body trial in which participants receive ACOU085, a Kv7.4 channel activator, in one ear and a placebo in the contralateral ear. The study is currently being conducted at 13 leading German ENT university clinics and is still actively recruiting.
“This marks a significant milestone on Acousia’s journey to offer a treatment for the prevention of permanent hearing loss caused by cisplatin,” said Professor Hubert Löwenheim, Chair of the Department of Otolaryngology - Head & Neck Surgery at Tuebingen University and Scientific Supervisor of the study. “Preventing this often overlooked side effect is critical for cancer patients. Notably, all PROHEAR participants who have received ≥300 mg/m² of cisplatin to date have developed ototoxicity. This is higher than reported in most, if not all, previous studies.”
The PROHEAR Study is on track to complete enrollment by the end of the second half of 2025. For more information, visit clinicaltrials.gov.
ACOU085 (INN: bimokalner) is a first-in-class, small-molecule, etiology-agnostic otoprotective drug-candidate delivered using standard transtympanic administration of a proprietary, slow-release gel formulation. Ototoxic hearing loss is a typical, severe, and permanent side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells (OHCs). ACOU085 modulates a biologically validated target, the KCNQ4-encoded Kv7.4 potassium channel of the OHCs, and has demonstrated significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity in preclinical models.
Contact
Tim Boelke, M.D.
boelke@acousia.com
www.acousia.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored17.11.2026 16:00:00 CET | Press release
Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies. Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery. Titia große Broermann: " this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”
PARACELSUS MEDICAL UNIVERSITY: PHARMACY PROGRAM GOES INTERNATIONAL16.11.2026 09:00:00 CET | Press release
Starting in the fall of 2027, the “Pharmacy and Pharmaceutical Sciences” program will be the first English-taught pharmacy program in the German-speaking region to qualify students to work across a range of pharmacy roles and settings.
Infomaniak and Gruyère Energie develop a data center project in Bulle designed to limit its footprint13.11.2026 13:41:04 CET | Press release
Geneva and Bulle, 13 November 2026 – Infomaniak SA (SIX: INFO), a Swiss cloud provider, and Gruyère Energie SA announce that the planning application for a data center in Bulle will be put on public display on 13 November. Planned for 2028, this next-generation facility is intended to meet growing digital needs while reusing the heat produced by its servers in the existing district heating network. Its planned IT capacity of 2.5 megawatts (MW) is twice that of Infomaniak’s most recent data center, in Geneva. The project remains modest in size.
HEIDELBERG sees sequential improvement in business performance in a challenging geopolitical environment12.11.2026 09:07:04 CET | Press release
• Incoming orders high in second quarter of financial year 2026/2027 and around 3 percent higher after six months compared with equivalent period of previous year • Sequential increase in sales and EBITDA margin during financial year • Focus on strategic priorities – integration of manroland sheetfed proceeding according to plan • Geopolitical crises and advance outlay hit profitability • Forecast for financial year 2026/2027 – stable sales and adjusted EBITDA margin of between 5.6 and 6.6 percent
Polarise plans to add roughly 150 megawatts of new AI capacity in Germany by the end of 2028 - Named “Hidden Champion” by the German AI Association12.11.2026 08:49:30 CET | Press release
Upcoming AI Factories will be established in Bavaria, Hesse, and North Rhine-Westphalia - the award recognizes the development of sovereign AI infrastructure
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom